- Home
- CERO vs APVO Comparison
CERO vs APVO Comparison
Compare CERO & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERO
- APVO
- Stock Information
- Founded
- CERO 2017
- APVO 2016
- Country
- CERO United States
- APVO United States
- Employees
- CERO N/A
- APVO N/A
- Industry
- CERO
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- CERO
- APVO Health Care
- Exchange
- CERO Nasdaq
- APVO Nasdaq
- Market Cap
- CERO 3.5M
- APVO 4.1M
- IPO Year
- CERO N/A
- APVO N/A
- Fundamental
- Price
- CERO $8.38
- APVO $2.92
- Analyst Decision
- CERO Strong Buy
- APVO Strong Buy
- Analyst Count
- CERO 2
- APVO 1
- Target Price
- CERO $45.00
- APVO $5,920.00
- AVG Volume (30 Days)
- CERO 3.3M
- APVO 6.7M
- Earning Date
- CERO 08-13-2025
- APVO 08-07-2025
- Dividend Yield
- CERO N/A
- APVO N/A
- EPS Growth
- CERO N/A
- APVO N/A
- EPS
- CERO N/A
- APVO N/A
- Revenue
- CERO N/A
- APVO N/A
- Revenue This Year
- CERO N/A
- APVO N/A
- Revenue Next Year
- CERO N/A
- APVO N/A
- P/E Ratio
- CERO N/A
- APVO N/A
- Revenue Growth
- CERO N/A
- APVO N/A
- 52 Week Low
- CERO $6.71
- APVO $2.81
- 52 Week High
- CERO $895.40
- APVO $485.37
- Technical
- Relative Strength Index (RSI)
- CERO 44.55
- APVO 34.14
- Support Level
- CERO $8.50
- APVO $2.89
- Resistance Level
- CERO $9.02
- APVO $3.05
- Average True Range (ATR)
- CERO 0.67
- APVO 0.19
- MACD
- CERO -0.03
- APVO 0.22
- Stochastic Oscillator
- CERO 5.58
- APVO 10.54
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.